Bronchopulmonary lesions in chronic inflammatory bowel diseases


Cite item

Full Text

Abstract

The paper reviews the literature on bronchopulmonary lesion, one of the least studied systemic manifestations associated with inflammatory bowel diseases (IBD). Knowledge of the entire diversity of extraintestinal manifestations of IBD, including respiratory diseases, allows clinicians to optimize their diagnosis and treatment as the asymptomatic course of the latter may lead to the development of severe respiratory complications. The detection of bronchopulmonary pathology in its early period or during current therapy contributes to the objective assessment of the pattern of the disease, to the correction of treatment and improvement of disease prognosis.

References

  1. Rogler G., Scholmerich J. Extraintestinal manifestations of inflammatory bowel disease. Med. Clin. 2004; 99(3): 123-130.
  2. Kelly M. G., Frizelle F. A., Thornley P. T. et al. Inflammatory bowel disease and the lung: is there a link between surgery and bronchiectasis? Int. J. Colorect. Dis. 2006; 21(8): 754-775.
  3. Lichtman S. N., Wang J., Sartor R. B. et al. Reactivation of arthritis induced by small bowel bacterial overgrowth in rats: role of cytokines, bacteria, and bacterial polymers. Infect. and Immun. 1995; 63: 2295-2301.
  4. Storch I., Sachar D., Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm. Bowel Dis. 2003; 9(2): 104-115.
  5. Teague W. G., Sutphen J. L., Fechner R. E. Desquamative interstitial pneumonitis complicating inflammatory bowel disease of childhood. J. Pediatr. Gastroenterol. Nutr. 1985; 4(4): 663-667.
  6. Robertson D. A., Taylor N., Sidhu H. et al. Pulmonary permeability in coeliac disease and inflammatory bowel disease. Digestion 1989; 42(2): 98-103.
  7. Camus P., Piard F., Ashcroft T. et al. The lung in inflammatory bowel disease. Medicine (Baltimore) 1993; 72(3): 151-183.
  8. Songür N., Songür Y., Dopan I. et al. Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. J. Clin. Gastroenterol. 2003; 37(4): 292-298.
  9. Spira A., Grossman A., Balter M. Large airway disease associated with inflammatory bowel disease. Chest 1998; 113(6): 1723-1726.
  10. Fireman Z., Kivity S., Kopelman Y. Using artificial sputum in the evaluation of pulmonary involvement in Crohn disease. Am. J. Gastroenterol. 2000; 95(3): 730-734.
  11. Herrlinger K. P., Noftz M. K., Dalhoff K. et al. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am. J. Gastroenterol. 2002; 97(2): 377-381.
  12. Marvisi M., Fornasari G. Is the lung a target organ in inflammatory bowel disease? Recenti Progr. Med. 2001; 92(12): 774-777.
  13. Marvisi M., Bassi E., Civardi G. Pulmonary involvement in inflammatory bowel disease. Curr. Drug. Targets Inflamm. Allergy 2004; 3(4): 437-439.
  14. Marvisi M., Bassi E., Bonassi R. et al. DLCO correlates with intestinal inflammation in ulcerative colitis, but albuminuria does not. Minerva Gastroenterol. Dietol. 2007; 53(4): 321- 327.
  15. Tzanakis N., Bouros D., Samiou M. et al. Lung function in patients with inflammatory bowel disease. Respir. Med. 1998; 92(3): 516-522.
  16. Mohamed-Hussein A. A., Mohamed N. A., Ibrahim M. E. Changes in pulmonary function in patients with ulcerative colitis. Respir. Med. 2007; 101(5): 977-982.
  17. Dierkes-Globisch A., Mohr H. Lung function of deviations in respiratory asymptomatic patients with inflammatory bowel disease. Intern. Eur. J. Med. 2002; 13(6): 385.
  18. Tunc B., Filik L., Bilgic F. et al. Pulmonary function tests, high-resolution computed tomography findings and inflammatory bowel disease. Acta Gastroenterol. Belg. 2006; 69(3): 255-260.
  19. Wilcox P., Miller R., Miller G. et al. Airway involvement in ulcerative colitis. Chest 1987; 92(1): 18-22.
  20. Black H., Mendoza M., Murin S. Thoracic manifestations of inflammatory bowel disease. Chest 2007; 131(2): 524-532.
  21. Coonar A. S., Hwang D. M., Darling G. Pulmonary involvement in inflammatory bowel disease. Ann. Thorac. Surg. 2007; 84(5): 1748-1750.
  22. Marten K., Fend F., Hautmann H. et al. Case report: Fatal acute exacerbation of usual interstitial pneumonia in ulcerative colitis. Br. J. Radiol. 2005; 78(932): 762-766.
  23. Hutfless S. M., Weng X., Liu L. et al. Mortality by medication use among patients with inflammatory bowel disease, 1996- 2003. Gastroenterology 2007; 133(6): 1779-1786.
  24. Haralambou G., Teirstein A. S., Gil J., Present D. H. Bronchiolitis obliterans in a patient with ulcerative colitis receiving mesalamine. Mt Sinai J. Med. 2001; 68(6): 384-388.
  25. Foster R. A., Zander D. S., Mergo P. J., Valentine J. F. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm. Bowel Dis. 2003; 9(5): 308-315.
  26. Casey M. B., Tazelaar H. D., Myers J. L. et al. Noninfectious lung pathology in patients with Crohn's disease. Am. J. Surg. Pathol. 2003; 27(2): 213-219.
  27. Pèrez C, Carlos; Erräzuriz C. Isabel; Brockmann V. Pablo; Gonzälez B, Sergio; Cofré L, Cecilia. Eosinophilic pneumonia caused by mesalazine: Report of one case. Rev. Med. Chil. 2003 Sep; 131(9): 1087-8; author reply 1088.
  28. Brechmann T., Heyer C., Schmiegel W. Methotrexate-induced pneumonitis in a woman with Crohn's disease. Dtsch. Med. Wschr. 2007; 132(34-35): 1759-1762.
  29. Ananthakrishnan A. N., Attila T., Otterson M. F. et al. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. Clin. Gastroenterol. 2007; 41(7): 682-688.
  30. Ceyhan B. Inflammatory bowel disease and lung. Tuberc. Thoraks 2006; 54(3): 292-298.
  31. Tagle M., Barriga J., Piceiro A. Crohn's disease associated with focal pulmonare lesion. Rev. Gastroenterol. Peru 2003; 23(4): 293-296.
  32. Charfi M. R., Dougui M. H., Bazar N. Bronchiectasis in a patient with ulcerative colitis. Eur. Respir. J. 2000; 15(1): 209- 212.
  33. Ward H., Fisher K. L., Waghray R. et al. Constrictive bronchiolitis and ulcerative colitis. Can. Respir. J. 1999; 6(2): 197- 200.
  34. Raj A. A., Birring S. S., Green R. et al. Prevalence of inflammatory bowel disease in patients with airways disease. Respir. Med. 2008; 102(5): 780-785.
  35. Wallaert B., Colombel J. F., Tonnel A. B. et al. Evidence of lymphocyte alveolitis in Crohn's disease. Thorax 1985; 87(3): 363-367.
  36. Rubin D. T., Hanauer S. B. Smoking and inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 2000; 12: 855-862.
  37. Sandler R. S., Sandler D. P., McDonnell C. W., Wurzelmann J. J. Childhood exposure to environmental tobacco smoke and the risk of ulcerative colitis. Am. J. Epidemiol. 1992; 135: 603-608.
  38. Lee J. C. W., Lennard-Jones J. E. Inflammatory bowel disease in 67 families each with three or more affected first-degree relatives. Gastroenterology 1996; 111: 587-596.
  39. Gursoy S., Guven K., Kula M. et al. Subclinical alveolar involvement in ulcerative colitis. Inflamm. Bowel Dis. 2005; 11(4): 372-375.
  40. Gil-Simön P., Barrio Andrés J., Atienza Sänchez R. et al. Bronchiolitis obliterans organizing pneumonia and Crohn's disease. Rev. Esp. Enferm. Dig. 2008; 100(3): 175-177.
  41. Casellas Jordá F. TNF-alpha inhibitors in inflammatory bowel disease. Med. Clin. (Barc.) 2004; 123(16): 627-634.
  42. Chang J. T., Lichtenstein G. R. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006; 3(4): 220-228.
  43. Behm B. W., Bickston S. J. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 2008; 23(1): CD006893.
  44. Rutgeerts P., D'Haens G., Targan S. R. et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-769.
  45. Garcia Vidal C., Rodriguez Fernändez S., Martinez Lacasa J. et al. Paradoxical response to antituberculous therapy in infliximabtreated patients with disseminated tuberculosis. Clin. Infect. Dis. 2005; 40(5): 756-759.
  46. Sandborn W. J. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr. Gastroenterol. Rep. 2003; 5(6): 501-550.
  47. Kevans D., Keegan D., Mulcahy H. E., O'Donoghue D. P. Infliximab therapy in Crohn's disease: a pragmatic approach? Aliment. Pharmacol. 2006; 24(2): 351-359.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies